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1 GENERAL PART 
1.1 INTRODUCTION 
1.1.1 The Phencyclidine-derived Designer Drugs 
In the late 1990s, a considerable number of new designer drugs from various (new) 
drug classes were seized in the German federal state of Hesse and the surrounding 
federal states. One of these substances was N-(1-phenylcyclohexyl)-propanamine 
(PCPr), a phencyclidine (PCP)-derived compound. Within a short period of time, further 
members of this new class of PCP-derived designer drugs appeared in the illicit drug 
market, namely N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA), N-(1-
phenylcyclohexyl)-2-methoxyethanamine (PCMEA), and N-(1-phenylcyclohexyl)-2-
ethoxyethanamine (PCEEA). The seized preparations contained either one compound 
alone or in mixtures with other designer drugs.1 In expectance of its appearance on the 
illicit drug market, a further homologue, namely, N-(1-phenylcyclohexyl)-3-
ethoxypropanamine (PCEPA), was synthesized as a reference substance for scientific 
purposes. Chemical structures of these compounds are shown in Fig. 1.  
All compounds have in common the phenylcyclohexylamine structure being substituted 
with different side chains at the nitrogen. In case of PCPr the side chain consists of a 
propyl moiety and in the other compounds of combinations of a propyl or ethyl moiety 
carrying a methoxy or ethoxy moiety. Introducing new substituents allows the drug 
abusers to create “legal” products which are not scheduled as controlled substances. 
Unfortunately, only little information on the pharmacological properties of these 
compounds is available.2 Due to structural similarities, they might be assumed to be 
similar to those of PCP or ketamine, which both act as antagonists at N-methyl-D-
aspartate (NMDA) receptors and have psychotomimetic as well as anesthetic 
properties.3 Furthermore, it has been reported that (1-phenylcyclohexyl)-amine, a 
known metabolite of PCP and of the above-mentioned PCP-derived compounds,4-7 
produced a long-lasting dose-dependent effect on the efflux of dopamine in the rat.8 A 
similar pharmacological profile of the above-mentioned PCP-derived compounds would 
clearly be in line with their abuse as designer drugs. 
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Fig. 1: Chemical structures of PCP-derived designer drugs. 
 
So far, no information about the metabolism of the PCP-derived designer drugs is 
available in the literature. However, for developing toxicological screening procedures, 
especially in urine, it is a prerequisite to know the metabolism of the compounds in 
question, especially if they are excreted in urine primarily or even exclusively in form of 
metabolites. Furthermore, data on the metabolism are needed for toxicological risk 
assessment, because the metabolites may play a major role in the toxicity of a drug.  
 
1.1.2 Drug Metabolizing Enzymes 
A wide variety of enzymes catalyze the metabolism of drugs and other xenobiotics. 
Their metabolites can be more or less toxic than the parent compound. The metabolic 
profiling of drugs is, therefore, necessary to assess their effects and toxicity.9 
Cytochrome P450 (CYP) enzymes are responsible for oxidative and, to a minor extent, 
reductive metabolic transformations of drugs, environmental chemicals and natural 
compounds. CYPs are heme-containing, membrane-bound enzymes (“heme-thiolate 
proteins”) detected in both prokaryotes and eukaryotes. The enzymes were given their 
names because their complexes with carbon monoxide under reductive conditions show 
an absorbance maximum at about 450 nm. In mammals the enzymes can be identified 
in nearly every tissue, being most abundantly present in the liver. The CYP superfamily 
1 General Part 3 
 
has been classified in different families in accordance to the degree of homology of 
amino acid sequence in their protein structures. CYP enzymes having ≤ 40% homology 
in their amino acid sequence are classified in different families which are designated by 
Arabic numbers, for example, CYP1. Each family is further divided into subfamilies of 
enzymes. The enzymes within a mammalian subfamily have ≥ 55% sequence homology 
and are designated by capital letters, for example, CYP1A. An Arabic number is used 
for designating individual enzymes within a subfamily, for example, CYP1A2.10 In 
humans, 18 CYP families with 43 subfamilies and 57 CYP isoenzymes are known so 
far, of which only 3 families with 7 subfamilies and 12 CYP isoenzymes are relevant for 
drug metabolism,11 namely CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, 
CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5.12  
 
 
Fig. 2: Relative quantities of CYPs in human liver and their relevance in drug metabolism. Left side: 
human CYP-expression in the liver. Right side: involvement in xenobiotics metabolism. 
 
The remainder is responsible for the transformation of endogenous biomolecules, for 
which reason they are called “housekeeping enzymes”. Fig. 2 illustrates the 
abundances of CYPs in human liver and their importance in xenobiotic metabolism. 
Some CYP genes are polymorphically expressed, leading to variabilities in patterns of 
drug metabolism. 
Over its long history of more than 3.5 billion years, the CYP superfamily of enzymes has 
developed remarkable versatility. The primary catalytic function of CYPs was identified 
as transfer of one oxygen atom from molecular oxygen into various substrates (Fig. 3). 
A coenzyme, cytochrome P450 oxidoreductase (OR), is essential for CYP catalytic 
function, and cytochrome b5 can stimulate catalytic activities of some enzymes.13  
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Fig. 3: The cytochrome P450 redox cycle. 
 
Human liver derived enzyme preparations, e.g. human liver microsomes (HLM) contain 
a natural mixture of CYPs. Chemical inhibitors, immunochemical inhibitors, and/or 
correlation analyses with marker activities must be used to obtain information on which 
enzymes are performing specific biotransformations. In contrast, only a single active 
CYP is present in preparations of cDNA-expressed enzymes. Inhibitors and correlation 
analyses are not needed, because the mentioned assignments can be performed by 
direct incubation of the drug with a panel of individual CYPs. However, the balance of 
enzymes, present in vivo, is lost.13 Bacteria, yeast, baculovirus and several mammalian 
cells have been used to produce a wide range of catalytically active CYPs. The 
baculovirus system offers high-level expression of both the CYP and OR, and are 
therefore advantageous for metabolism studies of all kinds, especially for low turnover 
substrates. The development of the cDNA-bearing virus is relatively time-consuming 
and labor-intensive, but baculovirus infected insect cell microsomes are commercially 
available. However, because the enzymes are produced transiently in the insect host 
cells, exact harvest time can have a pronounced effect on the activity of the final 
preparation.14  
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When a CYP enzyme activity is modified by induction or inhibition, the biological activity 
of the xenobiotic substrate can be altered considerably. Such effects are called drug-
drug, drug-chemical or chemical-chemical-interactions. Such interactions can modify the 
disposition of xenobiotics.10,15,16 Hence, identification of the human enzymes involved in 
the metabolism of specific drugs is becoming increasingly important for drug 
development. Such identifications should consider two processes involving the new 
drug: metabolism and inhibition. The identification of enzymes involved in metabolism of 
the new drug allows prediction, based on knowledge of the ability of co-administered 
drugs to inhibit the same enzymes, of which co-administered drugs may inhibit the 
metabolism of the new drug. This information can also be used to predict individual 
variability based on known metabolic polymorphisms.13 However, also the new drug can 
act as an inhibitor what may lead to interactions with co-administered drugs. 
 
1.1.3 Biotechnological Synthesis of Drug Metabolites  
Reference standards of drug metabolites are needed for studies on their 
pharmacokinetic characterization of their formation. However, such metabolite 
standards are often not commercially available, particularly in the case of new 
therapeutic drugs or drugs of abuse. The classical chemical synthesis of drug 
metabolites can be cumbersome and stereochemically demanding and hence go 
beyond the possibilities of most biochemistry or pharmacology/toxicology oriented 
laboratories. Custom made metabolite standards are a possible but usually time-
consuming and very expensive solution. 
Recently Peters et al.17 demonstrated that biotechnological synthesis of drug 
metabolites using CYP enzymes can be a versatile alternative to classical chemical 
synthesis. They used the pyrrolidinophenone-type designer drug 4’-methyl-α-
pyrrolidinobutyrophenone (MPBP) as model substrate and human CYP2D6 
heterologously expressed in strain CAD58 of the fission yeast S. pombe as model 
enzyme. Furthermore Peters et al.18-20 demonstrated biotechnological synthesis of drug 
metabolites of phencyclidine-derived designer drugs. These drugs metabolites were 
used as reference standard for the characterization of the kinetic profile of O-
dealkylation of PCEPA, PCMPA, PCEEA, and PCMEA. 

1 General Part 7 
 
1.2 AIMS AND SCOPES 
The knowledge of the metabolic steps of a drug (of abuse) is a prerequisite for 
developing toxicological screening procedures, especially if the compounds are 
excreted in urine only in form of their metabolites. 
The knowledge of the involvement of particular CYP isoenzymes in the 
biotransformation of a new drug is a prerequisite to predict possible drug-drug-
interactions, inter-individual variations in pharmacokinetic profiles and increased 
appearance of side effects and serious poisonings.21,22 However, such risk assessment 
is typically performed for substances intended for therapeutic use, but not for drugs of 
the illicit market. In addition, there is good evidence that genetic variations in drug 
metabolism have important behavioral consequences that can alter the risk of drug 
abuse and dependence.23 The phencyclidine derived compounds were not yet 
investigated in any of these respects, so that the aims of the presented studies were: 
 
• Identification of the metabolites 
• Development of a urine screening procedure 
• Identification of the cytochrome P450 isoforms involved in the main metabolic steps 
• Characterization of the kinetic profile of the involved CYP isoenzymes in the main 
metabolic steps 
 

2 Original Publications 9 
 
2 ORIGINAL PUBLICATIONS 
2.1 NEW DESIGNER DRUG N-(1-PHENYLCYCLOHEXYL)-3-ETHOXYPROPANAMINE 
(PCEPA): STUDIES ON ITS METABOLISM AND TOXICOLOGICAL DETECTION IN 
RAT URINE USING GAS CHROMATOGRAPHIC/MASS SPECTROMETRIC 
TECHNIQUES6  
(DOI:10.1002/JMS.1058) 
 
2 Original Publications 11 
 
2.2 METABOLISM AND TOXICOLOGICAL DETECTION OF A NEW DESIGNER DRUG, 
N-(1-PHENYLCYCLOHEXYL)PROPANAMINE, IN RAT URINE USING GAS 
CHROMATOGRAPHY–MASS SPECTROMETRY4 
(DOI:10.1016/J.CHROMA.2007.11.002) 
 
2 Original Publications 13 
 
2.3 NEW DESIGNER DRUGS N-(1-PHENYLCYCLOHEXYL)-2-ETHOXYETHANAMINE 
(PCEEA) AND N-(1-PHENYLCYCLOHEXYL)-2-METHOXYETHANAMINE 
(PCMEA): STUDIES ON THEIR METABOLISM AND TOXICOLOGICAL DETECTION 
IN RAT URINE USING GASCHROMATOGRAPHIC/MASS SPECTROMETRIC 
TECHNIQUES7 
(DOI:10.1002/JMS.1312) 

2 Original Publications 15 
 
2.4 METABOLISM AND TOXICOLOGICAL DETECTION OF THE DESIGNER DRUG 
N-(1-PHENYLCYCLOHEXYL)-3-METHOXYPROPANAMINE (PCMPA) IN RAT 
URINE USING GAS CHROMATOGRAPHY–MASS SPECTROMETRY5 
(DOI:10.1016/J.FORSCIINT.2008.09.001) 

2 Original Publications 17 
 
2.5 IDENTIFICATION OF CYTOCHROME P450 ENZYMES INVOLVED IN THE 
METABOLISM OF THE DESIGNER DRUGS N-(1-PHENYLCYCLOHEXYL)-3-
ETHOXYPROPANAMINE AND N-(1-PHENYLCYCLOHEXYL)-3-
METHOXYPROPANAMINE24  
(DIO: 10.1021/TX8001302) 

2 Original Publications 19 
 
2.6 INVESTIGATIONS ON THE CYTOCHROME P450 (CYP) ISOENZYMES INVOLVED 
IN THE METABOLISM OF THE DESIGNER DRUGS 
N-(1-PHENYLCYCLOHEXYL)2-ETHOXYETHANAMINE AND 
N-(1-PHENYLCYCLOHEXYL)-2-METHOXYETHANAMINE25  
(DOI: 10.1016/J.BCP.2008.10.024) 

3 Conclusions 21 
 
3 CONCLUSIONS 
The metabolism studies presented here showed that the designer drug PCEPA, 
PCMPA, PCEEA, PCMEA, and PCPr were mainly metabolized by O-dealkylation, 
hydroxylation of the cyclohexyl ring in different positions, hydroxylation of the phenyl 
ring, oxidation to the carboxylic acid, N-dealkylation, and combinations of these steps. 
As metabolic phase II reactions partial glucuronidation and sulfation were observed. 
The developed screening procedures allowed the detection of the studied compounds in 
rat urine after administration of common drug abusers' doses mainly via their 
metabolites. Assuming the similar metabolism in rats as in human, it can be concluded 
that the procedure should also be applicable for human urine screening in clinical or 
forensic cases.4-7 
In vitro studies showed that in the case of PCEPA, PCMPA, PCEEA, and PCMEA the 
O-dealkylation was the main metabolic step. This metabolic reaction was catalyzed by 
different CYPs. It could be concluded that the decreasing side-chain length of the 
compounds was associated with a higher contribution of CYP2B6. In accordance with 
the decreasing involvement of CYP2B6, the number of CYPs involved and their 
contributions increased with increasing side-chain length.25 The chemical inhibitor 4-(4-
chlorobenzyl)pyridine (CBP) reduced metabolite formation in pooled HLMs in the case 
of PCEPA, PCMPA, PCEEA, and PCMEA. The chemical inhibitor quinidine reduced 
metabolite formation in pooled HLMs in case of PCEPA and PCMPA. Examinations with 
HLMs from CYP2D6 poor metabolizers showed a reduction of metabolite formation for 
PCEPA and PCMPA.  
In the case of the O-dealkylation of PCMEA and PCPr in humans, CYP2B6 showed a 
major or even exclusive involvement. Considering this major involvement of CYP2B6, 
simultaneous intake of potent CYP2B6 inhibitory drugs, e.g. triethylene-
thioposphoramide (thiotepa), ticlopedine, clopidogrel,26,27 or several antidepressants28 
might lead to a decreased clearance of PCMEA or PCPr and, consequently, to elevated 
plasma concentrations. However, the clinical relevance of such interactions remains to 
be established.24,25 
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4 SUMMARY 
In the presented studies, the phencyclidine-derived designer drugs PCEPA, PCMPA, 
PCEEA, PCMEA, and PCPr were investigated regarding their metabolism and their 
toxicological analysis in urine. Furthermore, CYP isoform dependence of the main 
metabolic step and characterization of their kinetic profile were elucidated. The 
phencyclidine derived compounds were mainly metabolized by O-dealkylation, followed 
by oxidation to the corresponding acid, hydroxylation of the cyclohexyl ring in different 
positions, hydroxylation of the phenyl ring, N-dealkylation, and combinations of these 
steps. Phase II reactions consisted of partial glucuronidation and/or sulfation of some 
phase I metabolites. In the case of PCEPA, PCMPA, PCEEA, and PCMEA, the target 
analytes for the toxicological analysis were the derivatized O-dealkyl metabolites and 
their hydroxy isomers. In case of PCPr they were the mono-hydroxy metabolites, 
dihydroxy isomers and N-dealkylated mono-hydroxylated isomers. The main metabolic 
step of PCEPA, PCMPA, PCEEA, and PCMEA was catalyzed by different CYP 
isoforms. In case of the O-dealkylation of PCMEA in humans simultaneous intake of 
potent CYP2B6 inhibitory drugs, might lead to a decreased clearance of PCMEA.  
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6 ZUSAMMENFASSUNG 
In dieser Dissertation wurden der Metabolismus und die Nachweisbarkeit der neuen 
Designerdrogen des Phencyclidin-Typs PCEPA, PCMPA, PCEEA, PCMEA und PCPr 
im Urin untersucht. Ferner wurden die die Hauptmetabolismusschritte katalysierenden 
Cytochrom P450 (CYP) Isoenzyme und ihr kinetisches Profil aufgeklärt. Die PCPs 
wurden hauptsächlich durch O-Dealkylierung gefolgt von Oxidation zur Carbonsäure, 
Hydroxylierung des Cyclohexylringes in unterschiedlichen Positionen, Hydroxylierung 
des Phenylringes, N-Dealkylierung und Kombinationen aus diesen Schritten 
metabolisiert. Als Phase-II-Reaktionen wurden partielle Glucuronidierung oder 
Sulfatierung einiger Phase-I-Metaboliten gefunden. Die derivatisierten Metaboliten der 
Drogen aus den Hauptstoffwechselwegen (O-Dealkylierung, O-Dealkylierung und 
Hydroxylierung bei; PCEPA, PCMPA, PCEEA, PCMEA; Monohydroxylierung, 
Dihydroxylierung, N-Dealkylierung und Monohydroxylierung bei PCPr) waren die 
Zielsubstanzen im toxikologischen Nachweisverfahren. Die metabolischen Hauptschritte 
von PCEPA, PCMPA, PCEEA, und PCMEA wurde von unterschiedlichen CYPs 
katalysiert. Im Falle der O-Dealkylierung des PCMEA im Menschen könnte eine 
gleichzeitige Einnahme von Substanzen, die CYP2B6 hemmen, zu einer verminderten 
Clearance von PCMEA führen. 
